Prognose

Das durchschnittliche Kursziel der Analysten beträgt +13,31€(+183,80%). Der Median liegt bei +12,39€(+164,18%).

Kaufen	2
Halten	1
Verkaufen	1

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cara Therapeutics, Inc. (NasdaqCM: CARA) and Tvardi Therapeutics, Inc. Pursuant to the terms of the agreement, upon completion of the Merger, Cara shareholders are expected to own approximately 17.0% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are ad.» Mehr auf businesswire.com
CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc. - CARA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cara Therapeutics, Inc. (NasdaqCM: CARA) and Tvardi Therapeutics, Inc. Pursuant to the terms of the agreement, upon completion of the Merger, Cara shareholders are expected to own approximately 17.0% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are ad.» Mehr auf businesswire.com
Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split
STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “ Company ”), today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock and reduction in the total number of authorized shares of its common stock from 200,000,000 to 16,666,667 will be effective as of 5:00 p.m. Eastern Time on Monday, December 30, 2024.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte Cara Therapeutics Inc einen Umsatz von 2,30 Mio€ und ein Nettoeinkommen von −11,20 Mio€

(EUR)	Sep. 2024	YOY
Umsatz	+2,30 Mio	50,07%
Bruttoeinkommen	+2,30 Mio	26,55%
Nettoeinkommen	−11,20 Mio	57,69%
EBITDA	−9,38 Mio	65,58%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+21,45 Mio€
Anzahl Aktien	4,57 Mio
52 Wochen-Hoch/Tief	+10,58€ - +2,49€
Dividenden	Nein
Beta	0,5
KGV (PE Ratio)	−2,93
KGWV (PEG Ratio)	−0,21
KBV (PB Ratio)	+396,40
KUV (PS Ratio)	+2,69